AMAG Pharmaceuticals, Inc. AMAG and Allos Therapeutics, Inc.
ALTH today announced that they have entered into a definitive merger
agreement under which the companies will combine in an all-stock merger with a
total equity value of approximately $686 million.
The transaction is expected
to result in annual cost savings synergies of between $55 million and $60
million, the majority of which are expected to be realized in the first fiscal
year after closing.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in